MATAO trial for newly diagnosed Ovarian Cancer
MATAO-A clinical phase III trial on the use of letrozole maintenance therapy for newly diagnosed advanced ovarian, fallopian tube or peritoneal cancers.
MATAO- MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer: a randomized double-blinded placebo-controlled multi-center phase III Trial including LOGOS (LOw Grade Ovarian cancer Sub-study) (ENGOT-ov54/Swiss-GO-2)
For patients, specific criteria have to be fulfilled to participate in this trial. If a participation is possible, the patient have a 50 % chance on receiving a well know medication, which can prolong progression free survival after initial treatment. In addition, their quality of life and personal resilience (ability to manage crises) will be monitored. With a participation in a clinical trial, a participant supports the research and enables that other patients can benefit from new scientific findings.
This trial has been developed and initiated by the Swiss GO Trial Group, who functions as the lead sponsor in this respect and is supported by the German and Austrian Foundations for gynecological cancers, AGO and AGO-Austria, and is carried as part of the European study group on gynecological cancers (ENGOT): https://engot.esgo.org/clinical-trials.
Until beginning of July 2022, already 166 patients have been recruited and 79 randomized.
The MATAO trial as a whole is supported by peer-reviewed grants and funding from:
Stiftung Fürstlicher Kommerzienrat Guido Feger
Reliable Cancer Therapies (Anticancer Fund)
AGO Studiengruppe e.V
(kindly funds this study by providing the drug and placebo for this study and the transport to the CMO free of charge)